Table 4.
Variable | HR | 95% CI | P* |
---|---|---|---|
RX duration, days | |||
≤ 53 | 1.00 | ||
> 53 | 1.09 | 0.84 to 1.40 | .5219 |
Age, continuous | 1.03 | 1.02 to 1.04 | < .0001 |
Sex | |||
Female | 1.00 | ||
Male | 1.79 | 1.42 to 2.26 | < .0001 |
KPS | |||
90, 100 | 1.00 | ||
60,70,80 | 1.67 | 1.29 to 2.17 | < .0001 |
T stage | |||
T1/T2 | 1.00 | ||
T3/T4 | 1.49 | 1.18 to 1.87 | .0007 |
N stage | |||
N0 | 1.00 | ||
NX/N1/N2/N3 | 1.90 | 1.47 to 2.46 | < .0001 |
Total primary central axis dose (Gy), continuous | 0.97† | 0.96 to 0.99 | .001 |
Abbreviations: HR, hazard ratio; RX, overall treatment; KPS, Karnofsky performance score.
P value from χ2 test using the Cox proportional hazards model.
Interpretation: An increase in dose of 1 Gy means a decrease in the hazard of death by 3%; an increase in dose of 5 Gy means a decrease in the hazard of death by 13%; an increase in dose of 10 Gy means a decrease in the hazard of death by 24%.